Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D in Indolent Lymphoma (ILyAD)
NCT03078855Phase 3Completed
- Start
- Sep 2017
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (2 arms). Primary endpoint: Event Free Survival at 3 years. Started Sep 2017; status: completed.
Beyond the preview
Go deeper on NCT03078855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03078855.